Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies

In this Hematology Dialogues, Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies, participants will learn about the epidemiology and burden of Epstein-Barr Virus-positive (EBV+) and post-transplant lymphoproliferative disorders (PTLD), differentiate between current and emerging prognostic scoring systems for EBV+ and PTLD to inform treatment decisions, and evaluate the latest clinical evidence of emerging treatment options for EBV+ and PTLD. Experts will discuss hot topics in the field of EBV+ and PTLD as well as respond to patient cases and provide commentary relating to how they have responded to complex treatment decisions, thereby ensuring optimal clinical outcomes.

This independent satellite symposium is derived from the Society of Hematologic Oncology 2024 Annual Meeting, originally held on September 5, 2024.